Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.

mend a value of .100 for optimal fluconazole exposure when the MIC is tested using EUCAST methodology. Rough estimates of minimum AUC/MIC ratios of fluconazole against C. albicans isolated from bile and/or ascites [expressed as (bile or ascites Cmin.24 h)/MIC for Candida isolate in bile or ascites] were well above this threshold (.600) in our patients. We recognize that the absence of real AUC measurements may be a limitation, since our approach led to gross underestimation of drug exposure. However, the findings confirm the valuable role that fluconazole may have in the treatment of Candida cholangitis and/or peritonitis caused by susceptible strains in LTx patients, and supports the usefulness of TDM for optimizing fluconazole exposure in this setting.

[1]  A. Lazzarin,et al.  Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. , 2013, Journal of Antimicrobial Chemotherapy.

[2]  R. Kaul,et al.  Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen. , 2013, The Journal of infectious diseases.

[3]  C. Kovacs,et al.  Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men. , 2013, Journal of acquired immune deficiency syndromes.

[4]  A. Lazzarin,et al.  Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI‐sparing regimen for HIV‐infected naïve patients: 48‐weeks final results , 2012 .

[5]  P. Massip,et al.  Antiviral Effect of Maraviroc in Semen: A Case Report , 2012, Antiviral therapy.

[6]  D. Cooper,et al.  A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults , 2012, Journal of acquired immune deficiency syndromes.

[7]  Z. Grossman,et al.  Multicenter assessment of HIV‐1 RNA quantitation in semen in the CREAThE network , 2012, Journal of medical virology.

[8]  J. Mullins,et al.  Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission , 2011, Science Translational Medicine.

[9]  D. Podzamczer,et al.  Maraviroc concentrations in seminal plasma in HIV-infected patients. , 2010, Journal of acquired immune deficiency syndromes.

[10]  G. Lorello,et al.  Discordance in HIV‐1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma , 2009, HIV medicine.